ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Alseres Pharmaceuticals Inc (CE)

Alseres Pharmaceuticals Inc (CE) (ALSE)

0.005
0.00
(0.00%)
Closed September 19 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.005
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.005 52 Week Range 0.005
Previous Close
0.005
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

ALSE Latest News

Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. Conference Call to be Held Wednesday, August 1, 2012 at 11:00 a.m. Eastern...

Alseres Shares Begin Trading on the Pink Sheets OTC Market

HOPKINTON, Mass., May 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; Alseres) announced today that effective on Friday, May 8, 2009 trading in its shares on the NASDAQ...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

HOPKINTON, Mass., April 30 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; the Company) announced today that on April 24, 2009 it entered into an Amendment to License...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

HOPKINTON, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced that on January 8, 2009, it received notice from the NASDAQ Stock Market ("NASDAQ") that for the...

Boston Life Sciences, Inc. Changes Name to Alseres Pharmaceuticals, Inc.

HOPKINTON, Mass., June 8 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSINASDAQ:andNASDAQ:ALSE) today announced that its proposed name change to Alseres Pharmaceuticals, Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
52000.0050.0050.005660.005CS
156-0.005-500.010.010.005220.00834171CS
260-15.495-99.967741935515.515.50.005226.33729196CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GIPLGlobal Innovative Platforms Inc (CE)
$ 0.10
(9,999,900.00%)
605
ZHCLFZenith Capital Corporation (CE)
$ 0.07
(6,999,900.00%)
5.54k
AUSAFAustralis Capital Inc (CE)
$ 0.0101
(1,009,900.00%)
9.26k
ZAAGZA Group Inc (PK)
$ 0.0001
(9,900.00%)
512.76k
NWPNNow Corp (PK)
$ 0.0001
(9,900.00%)
5.76M
PFTIPuradyn Filter Technologies Inc (CE)
$ 0.000001
(-99.96%)
200k
GENNGenesis Healthcare Inc (CE)
$ 0.000001
(-99.91%)
2k
ATHXQAthersys Inc New (CE)
$ 0.000001
(-99.90%)
968
STIXFSemantix Inc (CE)
$ 0.0002
(-99.88%)
1.76k
GOSYGeckosystems International Corp (CE)
$ 0.000001
(-99.33%)
1M
AAPJAAP Inc (PK)
$ 0.0003
(-40.00%)
559.12M
AMLHAmerican Leisure Holdings Inc (PK)
$ 0.0003
(0.00%)
142.01M
ASIIAccredited Solutions Inc (PK)
$ 0.0006
(0.00%)
108.17M
HMBLHUMBL Inc (PK)
$ 0.00015
(50.00%)
100.64M
HCMCHealthier Choices Management Corporation (PK)
$ 0.000001
(-98.00%)
95.68M

ALSE Discussion

View Posts
Renee Renee 10 years ago
ALSE: effective December 31,2014 a one for 5,000 reverse split:

http://otce.finra.org/DailyList
👍️0
funnyG986 funnyG986 10 years ago
Sold mine here today for tax loss.
👍️0
Natural Trader Natural Trader 10 years ago
I dont have anymore shares sold cpl of months back
👍️0
accurate122000 accurate122000 10 years ago
Artist, Funny, Silver etc.
I also post on CASI, IN CASE THEY MAKE THIS BOARD DISAPPEAR LIKE THEY DID ON YAHOO.
Accurate
👍️0
accurate122000 accurate122000 10 years ago
Silver,
Please read my recent posts IF YOU ARE A HUGE HOLDER ?
Accurate
👍️0
accurate122000 accurate122000 10 years ago
The question is are you a huge stockholder, 6 figures in # of shares ? Otherwise after the reverse split it's not gonna help.
If so I've been down this road before and the legal fees can be high but if we band together maybe we can get fair value which will be substantial when they get FDA approval.
If we all, substantial holders, band together we can prevail $ wise.
Accurate
👍️0
funnyG986 funnyG986 10 years ago
what can you do buddy?
👍️0
accurate122000 accurate122000 10 years ago
Funny,
See my post to artist today.
CONTACT ME PLEASE.
ACCURATE12200
👍️0
accurate122000 accurate122000 10 years ago
Artist,
If you or any other holder of ALSE is a large holder please contact me ASAP. ON IHUB IS OK OR ANYWAY.
There is a reverse split happening and we need to coordinate all LARGE holders. Been here before with another issue and we NEED to work together.
SO ALL POSTERS PLEASE REPLY IF YOU HAVE A LARGE NUMBER OF SHARES.
As of Monday you will own 1/5000 of what # you now have, so if you don't have hundreds of thousands of shares you will have very little.
Accurate122000
👍️0
funnyG986 funnyG986 10 years ago
ALSE 0.03 X 0.0349. CHART SHOWS MM HAS LOADED THE BOTTOM



👍️0
Natural Trader Natural Trader 10 years ago
waiting for some news
👍️0
funnyG986 funnyG986 10 years ago
ALSE vol. chart seems someone preload 700k back in June. Phase III clinic trial.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/

👍️0
funnyG986 funnyG986 10 years ago
ALSE 10Q: 30.6M OS; Medication Altropane is in phase III clinic trial

As of July 31, 2014, there were 30,635,720 shares of the registrant’s Common Stock issued and outstanding.
👍️0
funnyG986 funnyG986 10 years ago
ALSE approaching end of phase III clinic trial. bidding some more 0.035, lotto ticket.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/
👍️0
Natural Trader Natural Trader 11 years ago
2012 NEWS// HOPKINTON, Mass., July 31, 2012 /PRNewswire/ — Alseres Pharmaceuticals, Inc. (OTC: ALSE) today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, “Navidea”) to license, [(123)I]-E-IACFT Injection (CFT), also called Altropane®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

“We are pleased to have completed this agreement with Navidea. With its focus, dedication, and imaging expertise, Navidea represents an ideal partner to complete the development and commercialization of this promising agent that may help millions of patients with movement disorders arrive at a more timely and accurate diagnosis,” said Peter G. Savas, CEO of Alseres.

“The diagnostic dilemma in movement disorders remains a pressing medical need that will continue to escalate as our world’s population ages,” said Dr. Mark Pykett, President and CEO of Navidea. “The addition of the CFT program is consistent with our growth strategy to build our precision radiopharmaceutical pipeline with later stage, high value diagnostics aimed at important medical needs.”

“We believe that CFT has the potential to be a best-in-class imaging agent to improve diagnostic accuracy by differentiating Parkinson’s disease from non-degenerative movement disorders, especially during the period soon after onset of symptoms,” said Dr. Thomas Tulip, Navidea’ s EVP and Chief Business Officer.

In January 2012, Alseres and Navidea executed an Option Agreement pursuant to which Navidea paid Alseres the non-refundable sum of $500,000 in exchange for the exclusive option to license the CFT program, to conduct its final due diligence review of the program and to prepare the paperwork necessary for the execution of the license.

Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop, and commercialize CFT. In connection with the execution of this agreement, Navidea will make a one-time sublicense execution payment to Alseres equal to (i) One Hundred Seventy-Five Thousand Dollars ($175,000) and (ii) issue Alseres 300,000 shares of NAVB common stock.

The license agreement also provides for contingent milestone payments of up to $2.9 million, $2.5 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.15 million shares of Navidea stock, 950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

Read more at http://www.redorbit.com/news/health/1112667041/alseres_pharmaceuticals_inc_reports_license_of_altropane_worldwide_rights_to/#kQGoiWI6Lj7RMZ2p.99
👍️0
Natural Trader Natural Trader 11 years ago
http://www.biocentury.com/companies/alseres_pharmaceuticals_inc
👍️0
Natural Trader Natural Trader 11 years ago
sure is
👍️0
funnyG986 funnyG986 11 years ago
ALSE 0.05 WOW! AIR THIN!!
👍️0
funnyG986 funnyG986 11 years ago
ALSE 0.035 LAST PIG. Company Believes Trial May Have Already Enrolled Enough Subjects to Achieve Statistical Significance
👍️0
Natural Trader Natural Trader 11 years ago
thnx G
👍️0
funnyG986 funnyG986 11 years ago
ALSE 0.035 interesting. Webpage shows 2014 and their product in phase III clinical developement

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/
👍️0
Silversurfer1 Silversurfer1 11 years ago
Anyone out there watching this ALSE?
👍️0
dr_c6 dr_c6 11 years ago
Why did they just spike 125%?
👍️0
dr_c6 dr_c6 11 years ago
What's going on here?
👍️0
xenod xenod 11 years ago
!!!
👍️0

Your Recent History

Delayed Upgrade Clock